ARWR - Earnings call transcript Q2 2021 | Arrowhead Pharmaceuticals Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead Vince.

Vincent Anzalone

Jessi. you, Thank everyone. Good afternoon for for joining XX, discuss you today us fiscal XXXX results its March Arrowhead’s second Thank to quarter XXXX. ended Dr. today President us management CEO, With from and are of Anzalone, the Christopher provide will an quarter; who Dr. overview Javier of provide update will the Myszkowski, Chief financials. on Officer, will who Ken an Financial and San Officer, our pipeline; give Martin, Medical our who Chief our a review

Medicine, James will James In available Discovery Chief Hamilton, Dr. our our and of call. Senior Hassard, Q&A addition, and the Officer, Translational be during today’s session President Vice Commercial of

you regarding and and the runway, those the statements expectations forward-looking begin, commercialization without cause expressed to comments expectations cash certain future and we All and XXXX. milestone I Arrowhead’s limitation Securities and management’s include around of meaning from the represent results future materially Before including could risks projected are are and would payments, development statements differ within than and other to licensing goals, like of plans, development, efficacy statements. statements statements during contain of the our to of numerous activities. Exchange and remind candidates, receipt uncertainties our Section call current Act These that expected statements. of drug historical These Act XXA actual fact, of subject of those Securities safety that of today’s to Section strategies statements respect the made with any forward-looking XXXX XXE forward-looking in

Christopher discussed call. of President I’d undertakes Anzalone, and Chris? the annual these and disclaims that Form any including to SEC and report concerning the any turn on intent Form forward-looking uncertainties, our XX-K update said, no call of CEO XX-Q. company. filings, quarterly on reports over duty the For today’s refer most risks please and statements like subsequent Arrowhead further recent to to on With to our details

Christopher Anzalone

today. and joining everyone thank you afternoon us for Good Vince. Thanks

discussed to going from have both the and to the population means is, any focus simply, where always physiological a driving all been can we benefit to and and This common As to from types diseases, it. getting has treating anatomical technology it Put our who body. in part of bring disease standpoint. means our a and rare, past, patients of standpoint

As such, we populations to various the production products by capabilities, address expand are improving scaling our constantly and convenience, of reach working administration dosing to schedule. optimizing our

targets We many make the reach new believe we of that constantly targeting treatment muscle. and TRiMTM and world many that years to have conditions to and types and the also proteins, validation adequate with to We skeletal striving have the to reach addressing have that are areas now and without only rare reality. of that silence We chronic proprietary options. distinct platform cell gaining RNAi third high and RNAi indications ago disease, such are was By HBV committed potentially our Arrowhead to even to of innovation cell cystic not clinical diseases always been body quarter diseases. fibrosis a on this clinical new It the and disease four be cusp showing and devoted considerable gene strive expand candidates year, that tumor, the rarer prevalence long we and and such to can throughout only for lung, relevant reaching AAT to as address then conditions expect disease. liver at different types, liver-expressed cardiovascular may as resources in thought effort

CF to to and with and have patients, to risk three these patients AAT expected types of data patients patients models those ARO-AAT liver ARO-ENAC data FSHD. pharma three. volunteers that potential of big not value that, in be with of ability and positions animal how a the including: in potential creation hundreds at data all and in says months, of been less a long-term, areas; of employees in data NASH the small and that XXX a ARO-HSD is It one not in data and with Three ARO-HIFX disease, than what tens number about value of mid, cell readouts cusp Think is breakthrough data relate in it thousands market healthy a may expect of may lead about over We couple our to NASH, billions nearing cell data-rich knowledge, $X and breakthrough employees renal value of having us on near, next Arrowhead field. in these addressed RNAi innovate in approximately with in be our market our for and by humans. in that carcinoma of ARO-DUXX for this billion it successfully a

in has with programs development. already pipeline undisclosed clinical studies, in candidates Our six additional preclinical liver directed

In last it. on type addition, same higher probability a lower provides the couple we this each We risk clinical builds other that once believe program in each seen achieve than validation, you’ve from and the candidate years, as over learnings cell successive of modalities. profile went success before

years. double potentially the We expect over our size few pipeline in to next

dramatically. the for new XX our to potential us and cell serve. we access months, growth We future future We the the expanding pipeline, continue leverage a this RNAi XX our represents field company, the Arrowhead hope type to and also so rapidly months about our for to for we that broadly. every It’s expand confidence will gives patients believe this believe hope of to

for progress value making near-term. the key pipeline in programs the potential current with our We’re drivers substantial on also

a of these. about Let’s few talk

review, us, results to some our exciting acceptance, some from the improvements a and community. biomarkers in improvements the monomer medical globule study, the liver want the last consistent treatment led to histological meeting, at XX-month pending in fibrosis; investigators ARO-AAT demonstrated dataset XXXX an of we relevant biopsy We announced in I health. ARO-AAT partners context. fuller and that abstract in were of both a label decrease the Z-AAT mutant of intra-hepatic a reduction to burden; First, consistent present in open study and results to to the results other substantial but intend and Takeda, at patient week. To upcoming These incredibly protein, polymer; provide

cirrhosis fibrosis achieved observed: four stages with during fifth stage, XX% after results of stage Two patients were assessment improvement in patients. with the the these patients one After important histological XX a to decreased XX patients the only stage globule decreased no histological in following reductions globule assessment demonstrated observed: fibrosis other to improvement a of of in worsening total results. worsening of want All treatment, Specifically, and, following and, fibrosis XX% baseline. one to by Metavir at of The two had the four in the weeks patients Z-AAT points highlight by improved two treatment intra-hepatic in or fibrosis XX%. with demonstrated or reductions patient. cohort total Metavir All five ARO-AAT Four achieved X, the of scores; results greater were greater intra-hepatic patients in scores; stage, weeks Z-AAT about fibrosis no few treatment in a five XX%. who I

were remarkably consistent. results the First,

patients what response studied. deeply is do in seeing it in expression, designed all have terms a to that that rate We XXX% was Z-AAT of reducing are been doing indicating ARO-AAT

new amazing is Z-AAT heal. the that ability saw rapidly Second, we protein to liver as silenced, has an

believe I for is XX they and disease, faster is than As other months dramatic XX% received healing grew been than this of hepatitis. of patients six such This a and XX% when to saw we who more I and only in has patients mentioned, treatment. regression for diseases as months received treatment of it NASH expected faster fibrosis, and of liver this shown viral

Based important potential stage the from of in data two humans our late-stage that disease disease, in that even which ARO-AAT six that The disease. the patients this FX animal after could on are been with is type of we with patients of I improve that point we fibrosis and months FX disease started improved from is treatment. The cirrhosis, trial Metavir believe work to support with third studied first only or rarely extensive the models, heal of to regardless in belief. rescue FX any liver this believed that late-stage has demonstrated have These cirrhosis, liver outcomes rapidly. stage, cirrhosis advanced rapidly.

In addition, and the to safety be consistent positive continue reports. assessments with previous

for protein and by is appears of a be augmentation is discontinuations is the biology crystal that therapy, to studied and an therapy. to clear. well monogenic efficiently seeks cannot We other on in had programs. function, whose required is other of those a date, into of Alpha-X accumulation ultimately is drug, have no caused regular that cause liver-directed due get is to globules, What consistent measures disease our aggregation lung is of with fibrosis. patients protein no ZAAT reverse and This by in was expectation insult. form example liver those great leads out polymers RNAi-based than study not have inflammation, augmentation which understood. target disease to the hepatocytes. cascade patients to to smart intervention. well-tolerated liver selection ARO-AAT ARO-AAT a already our changes generally It the that This entered do ARO-AAT any meaningful removing the cascade the of clinically mutant

strong that every ability indicate they encouraging forward improve heal, and is goal regulatory a to data liver believe we year. in a later to help path accelerated and We potential results, resilient ARO-AAT cascade. seek support to our to step interacting look organ with authorities with a this the approval. to Our These are appears the could

our Olpasiran, are AMG made ARO-AAT, to wholly called In good was which also These addition we’ve ARO-APOCX licensed owned, which Amgen. cardiometabolic programs. and are and ARO-ANGX, on XXX, progress formerly to

in recently to complete On first of lipoprotein(a) XXXX. in in disclosed elevated data enrollment is Phase with study the quarter, with expected program, half patients this latter Amgen X the expected a that be

IND programs. to the active, completed ARO-APOCX initiate four reviewed or ARO-ANGX, by in we which and two studies now intend are we For and were across FDA the United filings the more and States,

on but We each are here and the we targeting. will give running, designs are when the study up patient gets that more populations detail

patients XXX X which is over triglycerides focused Xb or ARO-APOCX, in mg/dL; mg/dL we Phase with in mg/dL; FCS. familial triglycerides For A hypertriglyceridemia, study patients Xb between three A Phase with XXX with studies: study intend syndrome, study patients to chylomicronemia Phase XXX and, in on a with patients start

is and with Xb elevated intend LDL we characterized triglycerides dyslipidemia For by mixed focused Phase a cholesterol, to start ARO-ANGX, elevated patients which on study.

For specific about we focused also the four mentioned to questions compounds, on additional we exploring studies are the smaller are but just are programs, primary the first. answer studies both initiating

in of to no also in ARO-DUXX myotoxic gene specific targets announced currently events protein, liver, are genetic of muscle clearance expression discuss muscle. target the we We specifically announcement of pipeline, ARODUXX. causes potential bring for, lead and which to gene intend near-term This is the facioscapulohumeral expectations built DUXX validation. X to of We as third but which There platform. FSHD. FSHD. are maintain timing dystrophy, a can is as want the and muscular DUXX, made that to clear for studies is the epigenetic targeted to there leads for and first I DUXX complete or encodes to strong DUXX, select associated overexpression TRIM across outside key is file strategy perfectly not homeobox biologic the or genetic Arrowhead’s quarter we for with weeks on begin to on disease effective regulatory with a candidate of Before clinical only designed FSHD few an our treatments fits highlight of patients to muscle our to believe double RNAi failure ARO-DUXX XXXX degeneration. human with suppression that I diseases treatment ago. a

and to so on to June on focus our planned It’s next very near I’m July. several going readouts. Let’s the for few to true especially This is a with be move busy mid-term. going months, events expectations and time and potentially important events the for for

from study results of initial order: the Ascending X. lavage, additional this Society study; Report Congress; second results important a in thereafter; deep continued X. IND-enabling preclinical Phase X. first couple host we in the stage. ARO-APOCX that plate of ARO-ENaC and a expect the near-term, into received study, the interim a programs X. results healthy just preclinical do with the and the first-in-human full to in patients first-in-human healthy knockdown initial have and open-label Report study; study. development Single we File XXXX FCS the on market initial regular with Phase X disease, X. in in AROAAT; first study discuss events data volunteers, cohort going that in and pulmonary the are following patients shortly potential that over XXXX and, data the International patients potentially space in and in already full Announce include This very Phase X. results bronchial FSHD likely at forward. with These Xb data path; biopsy patients from from Xb will clearly of Phase the results Research Dose expect study; the a the Report next a X. development gene the and are the XX-month expect ARO-HSD safety Dose months. We We first-in-human catalysts roughly the the from and Dose the interim first to Xb from ARO-ANGX the ARO-DUXX interim planned Fibrosis; webinar CTA Cystic the KOL Report ARO-HIFX the ARO-DUXX brushings in X. opportunity, first cohort Present for volunteers X. for

been efficiently, from will that to thrilled larger as DNA still of as part the San principles and have that are to to organization. Arrowhead see to the Martin. can continue speed, over Dr. be the and expanding call of even Javier to efficiency our execute a growing these With overview, like company. now Javier? I’d precision, turn in a culture beginning Innovation, have support capital We hallmarks pipeline been and this R&D we

Javier San Martin

of and Chris, good and study Since results talk afternoon shortly, I ARO-AAT XX-month you, open we patients reported label the full five want data on biopsy that top-line first from just program everyone. the to plan the XXXX Thank we first. about reporting on

consistent exciting. unexpected mentioned, at and fibrosis Chris early very regression these timepoints As the was

of The idea even Z-AAT fibrosis cascade in the lead relationship link. ultimately liver, relationship Z-AAT Importantly, itself. downstream and reduction we between the think biological is to intra-hepatic this inflammation remodel demonstrate clear accumulated reverse events of and between cirrhosis, that stage may liver and the substantial the key they The a allow and that protein cascade fibrosis. to Z-AAT heal at and is

next? the the years additional If Phase is the a what So, for dose adaptive recall, selection then in was X study of you design treatment idea and SEQUOIA study X/X with an at selected dose original patients. stage

have we regulators route more study, to open we study, have faster data thought then be discuss data will would a seen the encouraging the XXXX the make with potentially endpoints Given in into to NDA the context of label SEQUOIA generated. in all X a traditional approvable we Phase

completion next Phase have of We year. paired and to in enrollment the SEQUOIA the them are XX-month XX expect of nearing X biopsies for patients

addition, study, the paired us In from expect the to in approximately patients we XX label with have patients XX open which XXXX data gives biopsies.

multiple We timepoints dose data also from compare to able and levels. different will be with

discussing we to how We comprehensive For a We forward strongly AROAAT very look with that be feel form can’t rich this this will amount is an continue of enough picture disease, that performs. to have co-developed Takeda. substantial a is an the set data. of regulators. approval. of ARO-AAT will path orphan we support I to file to believe but the being NDA, accelerated say with some data data

and give the plan regulatory are interactions the IND to the the Takeda, transfer team are We Phase and to development at The studies this once is leading at time. still complete. lead X

ARO-HIFX ongoing at then earlier, a an Since preliminary meeting. release appropriate couple have initial ARO-HSD, months. fuller highlights studies, results expect mentioned data present provide over these likely are a medical interim we and ARO-ENaC, Chris readouts the set data press As from in we and will to next

included about buildup genetic cohorts breathing It epithelial Let’s leads mutation to start candidate rare ARO-ENaC, what is lungs. the CF. be for might designed available or therapeutic program. the each that RNAi and inhaled in to mucociliary is I consecutive data will three mucus by by dose strategy is a of CF occur with airway frequent Patients call which are can sodium of persistent cycle caused cycles. Repeat The ARO-ENaC talk and current Each days administer dose with cystic nebulized three a fibrosis, treat characterized and to our channel CF dehydration disease dose in lunginfections. target reduced to a and have later. or cycles dose is we transport. weeks ARO-ENaC, what placebo. experience receiving difficulty

on again study. three, for Phase day and is So, in patient and receives a day a cycles, example, one, if dose-escalating a nebulized XX, will dose then X/X XX. and receive dose on XX, two, two they ARO-ENaC

cycle levels, received We tolerability. at who have dose four safety a dose AROENaC volunteers, and normal XX single healthy administered assess in to different

We XX bronchoscopy CF of twelve baseline and brushings six with placebo. dose administered and XXX subjects controlled. ARO-ENaC also day in volunteers, additional bronchio-alveolar bronchial or of normal and ENaC lavage in three placebo XX the cycle with healthy is at knockdown patients portion These at have Patients two evaluate two an mg to study the – in one with receive of who and BAL, or patients. dose undergo cohorts it cohorts lung. includes these one ARO-ENaC each cycles patient The receive

stage. The received the complete at four placebo, of are and XX first still received we and patients, two is ARO-ENaC a dose six which of mg blinded cohort of follow up in

The a receive will XXX the of will XX second dose cohort of mg. receive mg a dose cohort and third

cohort. of we is interim cohorts, watching the across and tolerability be the healthy the and We closely four first be will volunteer cohort, the bronchoscopy knockdown cohorts most results bronchoscopy the healthy and CF What from cohort will safety on one reporting volunteer SAD the ENaC patients.

to FEVX, this active and lung in patients function. we CF with four on drug, expect changes cohort, be we able at to however lowest measuring dose do patient detect not only be the For also will

readout longer As and select lead improvements larger function. get to our genetic and disease sizes, target we of to strong. alcohol alcoholic population months for nonalcohol investigational in our are that a with a The higher treatment inhibition liver hope ENaC the able homogeneous ARO-HSD, is We and supporting planned NASH more and for as it to patient will liver doses, candidate sample coming lung clearance the the a data exposure, next is HSDXXBXX potential program over is disease. mucociliary related think

as with volunteers patients a normal are X/X in or as Phase conducting suspected We healthy in study well NASH. NASH

patients, We completed healthy dosing study purpose form the portion in liver of the Target HSDXXBXX cohorts tissue mRNA of two have in to to dose four In will in NASH in protein with volunteers of be engagement completed is with biopsies. of gene the single and suspected knockdown, in and target biopsy the study knockdown. this patients the assessed have NASH. the multiple-dose obtain evaluate or

study to we the histology. are in not is see This liver As mechanism expect intended any in change is reduce short changes duration, to assessing fat, MRI-PDFF. not in we so don’t

ARO-HIFX, or to knockdown clear we to will clinical program inhibit HIF-Xa readout of there We are expect but which which designed If early expression and target at carcinoma cell developers, target we signs, the validation. is see to production genetic believe strong has drug assess looking of health Phase a The efficacy. different is the show for encouraging reduce are can will near have last novel liver is gene a treat study be we very on cell difficult term at in but we most have is its confidence been a we RCC. in any towards renal for if to moving to and ability ARO-HSD’s other biomarkers focused to of a there safety, X area doses. NASH HSDXXBXX good

of cohorts efficacy, advanced the to study clinical on associated and currently conducting preliminary are genes. RECIST, with the a Phase RCC. evaluate HIF to determine dose-finding and dose, to X three Xb clear is assess HIFX-alpha ARO-HIFX, and safety of Phase post-dose and study cell designed in tumoral The We expression recommended pharmacokinetics based

able metastatic to protocol dosing is We two were can and These different added completed to samples processed, the should two having The be on the have with report quarter are cohorts to lesions chance analyzed. a heavily evaluated, so amendment We cohorts collection of in the last two study. patients biopsy made three in months. and those in tumor better a pretreated new patients that patients add of us challenging. to locations, give coming be

Financial as looking tumors suggesting be Officer. now for to as call HIFX levels to I will measurable data knockdown. will turn over Myszkowski, Ken delivery functional of We Chief the Ken? well Arrowhead’s

Ken Myszkowski

and you, afternoon Javier, good Thank everyone.

our obligations $XXX.X $X.XX million XX, our received of our million reported for the net fully-diluted in is our ended in to to $XXX.X toward we based periods the ended collaboration over $XX.X March net March continue payment anticipated the Takeda manufacturing $XXX with Revenue a agreements and of weighted in collaboration managing also the X per on the with process revenue average with of current of upfront and shares received from the share per work for quarter license recognized quarter collaboration of $XX.X This the XXXX. as services. Takeda upfront $X.XX to January. recognition payments revenue with Takeda. million trials remaining the clinical relates period be XX, compared The our a the of certain upon in outstanding. March fully-diluted for As on million of related average agreement payment years. Janssen, ended associated agreement signing quarter This weighted portion was performance due includes be million, will million, recognized completing million based approximately or was the milestones shares of we and $XXX outstanding, for XXXX today, both share the loss for was XXXX. XX, quarter March and XX, or compares loss $XX.X $XX.X Revenue Revenue ended million recognition portion XXXX the to

during $XX.X additive the Janssen XXXX March milestones would and This Any and expenses XX, is the million substantially $XXX.X were net increase R&D million, March cash March also operating costs by increased with to operating XXXX. to used revenue $XX.X increased discovery personnel operating the Net XX, the the $XX.X in this R&D agreements costs. continues projection. ended rate million, The candidate cash as increase quarter. this additional of the recognition our for primarily grow. performance compared from key The under quarter due January. to ended payment is due We provided and to Total March quarter compensation XX, activities non-cash by run Takeda was specific to headcount $XX million million XXXX be cash quarter ended complete. during quarter XXXX. change be activities for our XX, burn driver partners to upfront achieved with was ended estimate received in of Our collaboration stock to per $XX million is our compared

balance used Takeda, March $XXX.X by totaled to from XX, increase due to in upfront received our to million at cash our primarily at million cash September compared investments XX, Turning the offset our XXXX. and and The operating for XXXX, payment investments $XXX sheet, was activities. cash

were XX, million. will March With common the Chris. back now that call at Our shares outstanding I to XXXX, $XXX turn overview, brief

Christopher Anzalone

validation exciting is Operator? to the us are growth our the of TRiM own new people are to These options. next because is today. also represent Thanks open is towards would joining on broader to and is call now value The potentially being patients therapies treatment exciting as that represent this our upcoming future made tissue a Clearly diseases, adequate important in these us there phase and and our I initiating Ken. more readouts This with questions. and platform. serious data data readouts clinical they types expanding is a becoming What progress rapid creation. without holds your Thanks for is to potentially of advanced. their for the company remember. for lot for and progress again like promise pipeline of new Arrowhead pipeline

Operator

question of Jefferies. is first line Maury from Our the of Raycroft

now is Your open. line

Maury Raycroft

Hi all on and for questions. Congrats thanks my the taking everyone. progress

First question is ENaC. on

mg of next in and in you can plan more baseline dose cohort you XX informed data. pretty on volunteer the the any and degree by confidence for patients determined cystic healthy is or the And cohorts the histories. fibrosis about enrolling X patients or then can two X? FEVX So cohorts, X, specifics talk the your in And patient were with provide mg XXX potential and maximizing you on

Christopher Anzalone

the Thanks, sort there I answers leave give granular I’ll ones. for to and can more Maury. Sure. it Javier you broad, of

saw So doses any from healthy volunteers. were before chosen the data we

those initial doses based our, studies animal And GLP studies were solely so – models. these and talks on and other

tolerated. I we’ve gone healthy in mentioned least been it’s through so far, the And, think various we’ve individuals doses those a volunteers. the and past at and all well

that So, be forward changes And we to see we the seeing, are cautiously dose. as optimistic escalate any to will continue the case. we’re FEVX if looking in we

third FEVX a – question? we parameters came So, as the about question had they into was the study. And what I’m what sorry,

Maury Raycroft

you if on yes, And parameters can comment or FEVX that? histories, then the I patient guess,

Christopher Anzalone

Javier? Okay.

Javier San Martin

criteria, speaking, I’ll give study. similar Yes, you Vertex of to which sense generally so the a inclusion was

is kind study. it baseline, in this for So that’s XXX at patients of so XX the to range

these in the young all candidates in be XX those about [indiscernible] patients, more decided in FEVX part have study, will to or XX% feature, patient close most general than do from but population the it’s LCI New relatively young and of XX. relatively stat For and these study Zealand Australia so who average, surgical this is to so patients and and about which XX the cohort average,

Christopher Anzalone

this let the in me also, I prepared remarks. And mentioned

So, what, for let looking me here. you we’re tell

are think good analysis. for take looking the We [ph] important now. that in undergoing the knockdown bronch right cohort home that’s volunteer most healthy the We’re

Let’s see if knockdown. good getting we’re

think is I four that with just patients. this all cohort, we have first

course. we four low dose have a of is patients, CF on of active and cohort individuals first it’s The all drug

– FEVX focused difficult see And at so those we’re it small feels going good to in knockdown. to us again, like so numbers changes very is it’s be small it to on, really

clinical if good about past, see at those ENaC there shape – knockouts bogey in so the benefit I as that in show because heterozygous have did look XX% we in with a we’re we’ve our patients talked CF, a can the they think think I but heterozygous are they knockdown that the essentially now. if of you really right analysis genetic that’s did

Maury Raycroft

year? helpful. cohorts Got comment the and And back for knocked if see really end there’s from on it. we do data That’s that? the you the But X in follow-up can place the I’ll strategy to you if those in And down the queue. CF X and in last expect at then maybe ENaC cystic – any have cohorts potential for patients, one of fibrosis hop patients, could for

Christopher Anzalone

Yes.

So that’s a good question.

expect those cohorts So, next yes some on have would patients present and data we – question, Look year. in have I this to us yes, in CF two we for can at the first point patients expect the the those on that end to, do that we’re you those of the so, but do by hold dose James, CF address bronch we’ll the back, want and doing have about question those not yet year. patients? product I

James Hassard

that those volunteers patients right intent dose opted subjects bronchs already, is to, we’ve without and and same enrollment, that so currently knocked then more, obtain potential do a now the so CF at to to population bronch not the dose disease the the it’s because rare the data CF to presents Yes, to bronchs healthy just a patients hindrance and from levels.

Maury Raycroft

for very you Thank taking much sense. my questions. Makes

Christopher Anzalone

Maury. Thanks,

Operator

Next line of from Cantor. of Young question is Alethia the

open. now is line Your

we’ve think I lost Alethia.

Alethia Young

you me? hear Can

Christopher Anzalone

we got. Yes,

Alethia Young

Cool.

it work this or or do is mean, dose Sorry. FEV when like at of And levels with that? the how My that you’re XX% I this enzymes like, get we you just kind to on in the NASH then you or about Vertex will group histology like level, that, at some ENaC, to wanted on that of less target, kind confirm first is a of particular I think kind severe biopsy certain also the data patients where like, more And think of question just addition there’s lower, NASH, in looks it’ll, severe? right was things. just do knockdown the liver

Christopher Anzalone

Sure.

too in are exposure. we looking this short first not So, at study. histology It’s

to amenable – The is and just populations picking designed patient on really this we be pick therapy. really answer knockdown sort levels, is be just answer of or other We’re dose about to they’ll know. is that no, question more James not at will I knockdown really I’ll study there certain because let whether this looking think, we’ll don’t your that. based be Javier and are good one a that a

think The quite in studies silencing gene it’s if been good. populations, I certain know protective genetic This Javier, known to that? have patient does if would product too good. that appear has tell early this been you at a does more this don’t pronounced validation know I be quite of the genetic effect. confer it’s point, to

Javier San Martin

development that pretty make thinking Yes, lot with we’ve mechanical of and condition it as, there’s is different different is many I Javier a different been fashion. It’s couple this question. in comments, about and many NASH many, and with can drugs something because a really good causes, stages big

best So would what it is and say, be to down important to patient the start population. narrow

about We liver be what So to don’t believe it not, drugs will in for need a is don’t is There focus. had that or HSD NASH say it’s think to really to work with lot that development fat. metabolic. about that we’ll start about more are that believe we

So it’s was Chris genetic for disease. just to but NASH, the liver it positive, said data, more also for be as not because alcoholic like

I but that’s tune the is the the in Phase key work is to more step so to question how X you for be So now That NASH. I these. needs next that with this small field clinically think experts beyond tells of X, and of we’re any make in this the think think hint, done, line to about start hint to And really the about in next that it. fine an development right a working is development initial again, the these above Phase step

Christopher Anzalone

question. our translate The ENaC, could that however, a is, initial idea target drug success that’s around certain out and FEVX patients, answer don’t remind not point. this this say percentage, knockout what others, Vertex about any of Alethia the into, of improvement. Rather, the upon sort question great this I’ll patient putting of populations. I though, we’re your and We will And I you think not, at you business. and, is it of dependent have

who correct. population those CF able after, not no that no to to for It so who indicated know patients, are CFTR be charge, or are Here of instance, that are XX% the have, who no not [indiscernible] have these cetera. take are will – [indiscernible] those for the et

look, in given win we don’t a just have if that, show And options X% those therapeutic for any can again, parameters, because given think improvement a FEVX, right real so we they folks, that that’s these other now.

Going that’s forward, but the target can least that, initially we we expand can patient see if at population.

Alethia Young

a on of drive, a feel knockdown really level? or trying that NASH, do follow-up just get you for benefit need like fair. And particular? to is you XX% like one to deep it kind That’s this think I’m the just

Christopher Anzalone

I that knockdown for is better. think more

generally show knocking I only at I’d transcripts. we’re down if we pretty good we’re, as disappointed think knockdown, XX% I think because liver be

that. a And silencing high is think, I gene expect again, negative as not I better. phenotype it’s product. than with probably So There that as can does be you to get better would appear

not it’s level. but level, some to So go trying we’re titrate some to like not above

Alethia Young

helpful. cool. Thank Okay, you was very It very much.

Christopher Anzalone

Welcome.

Operator

the Next of of Rajavelu Esther question is from line UBS.

now open. is line Your

Esther Rajavelu

and the congrats this thank you question for on the Hey, all year. progress

So is first strategy like the sounds me, go for population decided here. patient the you’ve management. with two triglyceride to on broader It trial APOCX the from

progress about strategy segments you timing kind and around the in in can So commercialization talk patient of and different timelines enrollment each expectations broader offset may those three there? how trials of filing, and

Christopher Anzalone

Sure.

can our given in those think believe data an substantially triglycerides those those We and look probably X/X triglycerides. We trades know lower our there’s of X is, States So, above United patients, million are severe bit we Phase with we we that primary than lowering XXX, endpoint study. hypertriglyceridemia the here more focus there a alone. approval simply on patients really

a be pretty X quickly a talked that enrolled. also as market we there us. a once And more in believe a, market can we so, FCS study just interested we shortly. we straightforward because think Having everyone’s to yearlong study about, can market think are that We said the that’s Phase for initiate to get we seems that we much

a that and that a is XXX, in So there, that believe the XXX to to to XXX those study we’ll in But will allow going there. broader the reason to broader that from know quickly us really to the I patients, just start retain optionality. to market. be don’t or Phase doing Phase just population. that be want probably to X we’re be, I now get It also study you we’re to XXX would in an That to do Xb could get population, outcome study. mentioned reason we’re going market

optionality but to and I that want there want go such? the do we to the do going it do there, decide now, such Javier, to talk want go if We’re we can to quickly. time at

Javier San Martin

we about these the I be said, And safety really pool for say followed is will broad the Phase we’re to doing another hypertriglyceridemia. study we’re patients the because hypertriglyceridemia by of severe really approval have the Yes, to just describe Phase good able Chris FCS comment patients. facilitate be the profile focused and Xb one for want to a why severe X and first but the and population on filing would other in

where timing We’ve process APOCX severe the I other AMD go, speak. wouldn’t the concrete meeting protocols. started screening for be FCS we the wouldn’t than I got patients about So as in just hypertriglyceridemia very the where

of all program the So or the same kind time APOCX the after entire other. one testing a is either is, the month, about

planning population, about it’s will that registration and required Phase study hypertriglyceridemia, have study data believe severe year and clinical I a not be which outcome three we do, in things to get outcomes. will study one very think these clinical we’re broad enable for for the the X

X So rare also this triglyceride starting where biomarkers months. in case, ultra the Phase next a couple indication the of for FCS sufficient is in study

these So parts. it’s a very broad program with major three

Esther Rajavelu

at latest you the the Can file the by agent agents another that to planning you’re targeting being that considered one DUXX some muscle really Thank asset? then Got context you. that that preclinical talk of And the the it. have of about quickly, is others? you in program are other this

Christopher Anzalone

Sure. address James, that? could you and go

James Hassard

sure. Yes,

I’m that not with I that, the that that any to are of So, compounds. oligos referring seen you’re those preclinical data other have assuming preclinical some of targeting are that

targeting mediated we’re transform compounds think a early approach as other with [ph] a should is or quarter approach action sRNA given versus targeting use Chris or our a different little the using. think, targeting we sRNA next still those targeted preclinical. filing that And be of ligand, molecule within mentioned, with so. small the I antisense mechanism I transferring targeted with the that We are approach

Christopher Anzalone

data June Conferences. animal marks, mentioned at And in in the we as we the prepared be will FSHD presenting

we’re So data. the We those to and about are with think you we and, look forward excited sharing that data. good

candidate. We’re drug excited about the

Esther Rajavelu

okay. Right,

Christopher Anzalone

welcome. You’re

Operator

Sir, is open. your question now Sandler. Tenthoff Next line Piper line Ted is the of from of

Ted Tenthoff

you was do to to of of on. and just but the Thank asked as much so what opportunity? how competitive lot if sort of have Thank with going respect and market Right. you. respect the very been deliver DUXX, much. programs a I some to said the muscle Maybe questions there’s out I for it asked, there, this with apologize you you do see

Christopher Anzalone

Sure.

have The There bit. a a it a webinar expect dystrophy. know biology it think can of is we substantial look, the view FSHD. So, is is We designed on go way I stay therapies directly expression crystal substantial we’ll are market, animal We no causes a market down, And we that that those. protein tuned that to of this it there. The into here it’s knock in the dynamics the at muscular have. this look, good that that disease. for we clear. are we least continued models believe opportunity

of there’s such. a that respective to so, the James the People of see you’ll And in a nonclinical about we we ton I out data way thereafter webinar. market and some it. seen the we’ll data see And they’ve have very as generated, data there. sometime much about have not mentioned, competitors, haven’t talk We’ll, talked expect they, June, but

we’re hat good RNAi. our hanging are fact we so, pretty that And that on at on the

good the at liver. outside pretty We’re getting

We are be the think I we’ll the – first type – of to of we’ll the this be of clinic. first molecule the

we we’ll just stack we’ll – how so And see up.

Ted Tenthoff

it. I appreciate Perfect.

So to follow the data coming down.

Christopher Anzalone

Thanks, Yes. Ted.

Operator

from Next line Capital Luca of question is Markets. Issi RBC of the

line Your is open. now

Luca Issi

some given ongoing us you one give color on here? on AAT can FDA my directional with on [ph], one Fantastic. congrats question that plus all Thanks the the so, that could so where sufficient actually Is what is the much from maybe the SEQUOIA dialogue data for progress. from approval? if be confidence a quick first there taking If and comps think Maybe of X.X% any it accelerated on scenario should the XX via if for you trial impressive gives better you’ve there’s it’d case, XXXX integrates. patients be that the one an you to showing molecule the an then ENaC, second any something show is seller for got much. is Ionis your can the the color highest the FEVX seen And to dose. not there it. Thanks so that great. that here, Ionis's we mediated for you actually I in here Well, Javier we’ve improvement believe about case think receptor maybe uptake Wondering for

Christopher Anzalone

Yes.

the expect collaborative So, it’s past, we address that relationship It’s FDA. And We’ve question. tackle. just the to one so I’ll a don’t question. the with want those great good I continue. with that We’ll to had the a FDA AAT discussions and in have

this I to aligned And this, are the and, on possible that this people as liver with quickly regulators so know, move we we’ve medical to got can as patients. unmet as to offer, a how you real think need. see an I of We awful recognize we think, opportunity Look, to, get FDA forward unpack awful lot data to of an a good and other disease. help lot

in which we patient drug have us, possible. is paired so as route Javier people, what see for the we’re to regulators around prepared orphan for that, to course, of I all indication. biopsies see lot the We’ll quickly market want to an a And as going just group. and and as mentioned to want XX a is, think all We remarks, see,

them then about point. Javier apply you how, if we think we’ll want we that And this an have could talk for just the data there’s there. to just see So can’t at of enough to be lot ENaC? awful FDA,

Javier San Martin

Yes.

So, with, or that’s can in, related question of Well, to target in that will like experience our other what we And we’ll with to would level than see our whether that. to the a X% regard expectation. we knockdown would more X% ENaC other do tissue. and see be that certainly RNAis

or XX should knockdown, that’s of that mucociliary that percent we an eventually will in MCC translate and into So translate in FEVX. that into the the may expectation or clearance improvement improvement more see

it experience, knockdown very based point cells believe response that and previous and on clinical happen. the that therefore the do like, the into get We we’ll our have those be epithelial to ENaC successful the gene believe benefit. is will we’ll we So the that see

see, to MCC what which disease, we that’s believe, that aspect significant and going is in the very we that’s the of So improvement we’re knockdown the believe FEVX clinical and ultimately. consequences

Christopher Anzalone

Again, and maybe it’s on as noisy only an some of course, this we’re dose, awfully The And manage patients cautiously optimistic point. only not our because that beat at but low to measure. you a it that we expectations know trying four can here truly reason achieve it’s day readout I’m FEVX that. first to is

expect And like that so that to see is bit at sample a much. size to point in just that FEVX a changes asking small feels such

we of let’s so optimistic help and are can something patients. these have that wait some And just we cautiously that

Luca Issi

question. captured Maybe helpful. a over you’ve Super want it. follow-up I quick a Javier, to sure make Got there, just super

better we it not factor should have great. better potentially you. are receptors will that integral approach would way a your a call within any will right or be versus to Is integrin receptor? – conjugating does a So is not guys that your you my about it understanding seller matter, uptake that Thank that ligand receptor conjugation have drive that siRNA integrin bind think

Javier San Martin

one? James, like that take would you to

James Hassard

that data, with matters, when we than I animal targeting the get we targeting the take down on knock one. ligand. ligand the targeting mean, Sure. use ligand I our better based can don’t

we looked but with course that’s antisense, our experience. animals sRNA Of and haven’t at that’s

Luca Issi

Gotcha. Thanks much. helpful. Super so

Operator

of is Trucchio Patrick line question the Next from of H.C. Wainwright.

open. now is Your line

Patrick Trucchio

thanks. Good Hi, afternoon.

strategy. Just a development capital Follow up couple questions me. of allocation and from questions on the

then capable of in and secondly, in based moving lung should potential specifically, in about the targets I’m tissue, the think in indication if in we the be And your specifically, validated of lastly, or target which could the think position? many forward that? programs HIFX, see of intention I on then clinically wondering tissue you programs capital are targets, build-out what and how about and liver, – additional platform pipeline mentioned strategy, you beyond other programs we for for And you’ve would how other programs. on knockdown wondering tissue, build-out I’m should part So, the evaluating particularly we current TRiM a past is possibly the muscle validated the particular product and of requirement genetically is extra successful tissues how extra-hepatic evidence with think looking based you these

thinking extra-hepatic is liver-targeted programs I’m what wondering for potential So, latest and partnering on the programs? the

Christopher Anzalone

lot at Patrick. lot The point on is as

something to that. how after? billion and The Takeda. XXX payments, right I that We’ve – we we’re don’t So, or know, Look, of payments million targets go answer more dollars possible milestone let’s around potential milestone Janssen, millions of dollars we change, Amgen, in I don’t can several from is now. milestone see, so to, million dollars well many from capitalized of I think XXX know got answer access possible payments the

at in I Put to So, capital enough of not access look, right of burden it do way, of we all capital-efficient some additional slowing to we’ve forward. And our manner. amount this compared you a we have competitors, anything capital these now. down we’re our look a it conservation, to Because programs got if think push capital. fair pretty

see frankly, what The programs. and near and in sort number we’re a And where dynamic capital point that we a do do capital constraint. So, of the question hold we good we question. of onto term a partner? We’ve for at then got least. I bandwidth not are don’t at is And what that’s

about to the less can’t no past, talked pipeline be our As company that that. our much company in commercialize is size all we’ve so large going

will And partnerships. some so no targeted do pun intended we

that You saw with Takeda.

You saw Amgen. that with

those at be talked When around to here seen U.S. the and some XX,XXX look drugs we synergy our of we Jim room. we pulmonologists to He’s of in the commercial looking cardio-metabolic to idea lipid we we’re We the in going That’s several some – be bets We’ll one idea with hold that now But target both of various lung clinics our packing We’ve XX,XXX that in candidate continue here to addressing place commercialized those important of idea the the the but APOCX somewhere our past, cetera. going where commercial to for in value clinic sell we’re this here, of in to like and make developing markets like and and reach is and right model et that. what number you assets, We’ve ANGX. There pipeline our addition we’ve got and into create pulmonologists. we see, part an so lung synergy leverage of infrastructure. do environment. commercial building large have is liked ARO-ENaC, some fair developing got in between to a see J&J. and why are molecules products. our with and infrastructure we the – You’ve onto do creation about our that Hassard we Similarly, some is drugs. cardiologists, the infrastructure. among of is to

Patrick Trucchio

XXXX. just HifXa, half And in then quick X the mentioned subunit it. a expected data Got on you another, if That’s of I next just Phase may sets and first follow-up the alpha helpful. that so

we’re milestones what or at Arrowhead any if wondering data to of advantages the ahead the and are relative time? are that expectations as payments ASO compared are and approach what just the expected to that So,

Christopher Anzalone

that the even give like, that public publicly X think a But to look look presented on to has Phase expect it’s or what a Yes, I Amgen publicly speaking, at guidance at versus like ASOs we’re in great any said has that about see advantage we to going out, come when as think they can’t in how good when least generally terms you the looks very is. – that. . really says excited and excited data going more to and what relates you data. that hepatocyte-directed frankly, potent Will to drug study half like give given be we’re with of I have granular that durable you it blowing first looks a ASOs, drug, contracts than data that’s XXXX that. that’s can’t key seen, to I We out this durability we’ve Look, sRNA think of the they

to a respect effect for you substantially a that out safety, also, a beat that as We catalytic in at profiles oligos. think antisense if an instance, And ASOs oligos will that has on more whereas oligos. think we look that they has data thrombocytopenia, antisense – know that generally seen safety there’s process. is they’re seen have antisense in sRNAs in with With a we in durability advantage as theoretical basis I but that back clinical than durable then will well the RNAi oligos, been just that no, basis. born antisense work to various been class that there’s consumptive respect there were no that’s clinical process, been we have

and that think work look partner right we We sighted – the Amgen. So, for they we think right got we’ll the drug.

Patrick Trucchio

much. Thank Got you That’s helpful. very it.

Christopher Anzalone

You’re welcome.

Operator

line Sachs. question from Salveen Next Richter Goldman the is of of

open. Your line now is

Sonia Gupta

FSHD Salveen. so skeletal assets? taking the This on much for you for Could chose first for why Sonia rationale for muscle is provide as our you the question. Hi, your thank indication you

Christopher Anzalone

can It know expressing the FSHD close that think get, think shouldn’t you continued right this. for We I for – target now. disease, I as or clear. hadrosaurus is as expression that you biology Thanks question. to that DUXX perfect is We and the a of Sure. perfect be is

that turn with can the that if around just that And SEQUOIA we does, this, alleviate disease. off then somebody should

run don’t over more will, I risk also think science mentioned, you as better than is We the of I less. if knockdown

of And knockdown so and get go further. to no level like not a it’s to have we certain

to it [indiscernible] known helpful troublesome that thing us. there’s no about that that’s target, – is biomarker. circulating is So there’s the The only

is desperate deal That’s our that need but new biopsies dose a more And determining of do levels, a to is when or a we’re our cumbersome, when not down look, going likely going to you this therapies. breaker. so that’s just what population forward, in bit is knocked determining, have patient little

we so could really that to we have think helpful And be them. something

Sonia Gupta

Thanks.

Christopher Anzalone

You’re welcome.

Operator

the from is Charda. question of line Nakae Keay Next of

Your line now is open.

Keay Nakae

Chris. Thanks,

siRNA, I’m is cells that provide development. a knocked kind other of other for payload? different the programs? other just words, initial your pulmonary So light get wondering your for administration, inhaled mentioned What epithelial read can you same to You the under patients. are pulmonary across conjugated in down data we that targets when could of the are and using same route CF

Christopher Anzalone

question. great a it’s Yes,

So, be this in using targeting expect that to to ligand. put gosh, yes, to the our programs we through me data we read, expect to pulmonary, We read better. do let able potential through these are here other same to and read

targeting We’re integrin. alpha-v beta-X

the one but down And expect would in knock out down early down expect other. down in that modified we would you sequence, well, that and if to that so knocked suggest the would the other ones, see we to see to we extent we in just as can should knock you they’re knocked I point reports in different as

readout on we there real various of is reads value a ton our and If I a of data bring why diseases. we there create product create, that we that’s franchise. ton us. can do a is so to is this ton think can so that of It a to And we drugs that ability pulmonary important create candidates and can can to

Keay Nakae

Okay, great. Thanks.

Christopher Anzalone

welcome. You’re

Operator

of from question Securities. B. the Riley is of Mayank Mamtani line Next

open. now is line Your

Mayank Mamtani

for Thanks team. afternoon, question. Good taking my

the can is, efficacy, lipon push one, ask a the ENaC. Yes, beyond of partial history can quickly the safety reason think kind you how you So make that on move much Phase Phase given And what the maybe beyond the function you now the quick of follow-up next that patients could you maybe comment you the on that testing just can target? that I do those versus basically, are profile, to determination builders X point and, X and you’re study? the like that at another or

Christopher Anzalone

Yes.

we go that data, but Sorry present so profile said we’ve line that not And but course, we the quite you look, was had class the we’ve I good. about but type, new lungs, until a what you We’ve a and and we’ve say have seen that no can’t that think, been never problems – that and when didn’t this, we to into in you’re that we a profile safety saw the has safety – but safety expect profile for of thrilled increase seen we’ve was we ask we’ll bringing publicly, been far. we been of drug. just new in what been so great, cell far, safety drugs into know new heard we’ve I discontinuations good particularly the detail really

wasn’t believe that defer on could and go go higher connection me the this, was, James to to. think on been I’ll that has need a to question reason here is, apologize no higher follow I again, you but I great you there I if

Mayank Mamtani

now? that you do then versus hear those fine into going and patients X can partial you X, how And balance hope a – Phase no me are Phase study I function.

James Hassard

question what safety studies dose. other increasing any findings have can that from not And us prevent escalation, in I would cover and safety the the seen clinical the the was and question? dose Yes. we on

Christopher Anzalone

on the Yes, you’re we about Phase Phase line. and X, for X talking again, had right, crackling considerations

did. the can you we limited in So, this. that enroll sure I’m not background patients Are we what

lung of above sort they something, a some do have then function level? So

James Hassard

NOLs certainly don’t are very No, population other Chris I at can’t as in at on, looking but patients study have now enrolling we’re don’t because reason there’s options, down that are early they point think road. this CFTR an mentioned we interested mean, any that it’s, the I just no the we And modulators on

Mayank Mamtani

that’s a expected could as just just its then just also by that out differences what had the Maybe given readout and on understand, in and maybe knock run deep Okay. is HPV HPV the two durable but you touch learnings and and between down have J&J, quick there to REEF-X REEF-X we different later on year, from the the studies? follow-up the that

Christopher Anzalone

of recall can’t various give I on to capsid as month as as of when again, XX I various six a the and permutations guidance stopping triple some combination be Janssen’s those could different any And very it have seen interesting. after it’s you what do I REEF-X a points might give also might months readout. therapy And I it’s then and guidance of certain that. end one Yes. drug, if has in of understanding s-antigen, other three parameters it’s certainly but inhibitors REEF-X on to with follow-up withdrawn. criteria. anything, And NUC of criteria, s-antigen my then there. reach that XXX If compounds, going course. That’s similar, can’t be therapy well. or is be RNAi any and patients its then or is permutations recall, a I haven’t

have NUC’s last done I think that several just given the over been topic years. studies the

those excited I’m to give you on I you look, any data I So, as those and as better also when are. see can’t come will guidance data out. And

Mayank Mamtani

And window going closer should we be month to type XX that question, month cell hear after new expect that given, final which are they you’ll you you getting think since Great. said to to from XX I muscle.

Christopher Anzalone

question. Sorry, you’re I’m couldn’t I answer I can’t that breaking joking. get up. it.

stay cell of on that, other give are are, you are we tuned but pop types on, the working to I can’t that in working going words we’ll… what’s guidance We of course, on several there any

Mayank Mamtani

Thanks You already have question. for my taking on. going

Christopher Anzalone

welcome. You’re

Operator

from SVB Foroohar line is Mani Leerink. question Last of the of

line Your now is open.

Mani Foroohar

couple A ones. quick guys. of Thanks

a First, about between within much gene where selection, tissues patient of et view accurate have of to how approach, that try mechanisms you’re target of who assessment And HIF, and a biopsy you’re of a diseases. patient effectively down about you pool follow-up the talking targeting have of is you’re kind the you better single question. then heterogeneous more cells. when cetera, knocked than population and heterogeneous there financial in a I more and and think across sample other the get targeting a can pursue a more cells much patients terms inherited in Are defined

Christopher Anzalone

Yes, that’s a good question.

see. are just – people we’re for respect can want we’d seeing we’re of answer on we part at study, to where the be if with And we follow the follow – is to in see enriched. might what and what is, there James, – what can that So We’ll that like to biopsy to you find now questions, what on and then add studies. in first do least patients looking can want you what the can see we’re we we anything might the you – to to see? going

James Hassard

Yes. Sure, percentage aspect And mean large of target the target it’s of all this study tumors. a drives sure. of about I course HIFX knockdown. RCC the critical really

is maximize yield. this critical in think a disease target ways to of biopsy we for this So, terms

tumors to certain biopsy that of I’m addresses think I to or not. number number we – improve ability your a cells if preferentially higher terms that others of types knockdown. measure question that and of have there’s yields tissue in asked tumor sites in give our over not just sure

Christopher Anzalone

those what Yes. we will getting you’re And be better response we a really see better difference if point if this. maybe responders, and tell know that how we also would those at much responders. immigrants And think. can below of forward This if nice in don’t rates, can teach answer we study, out responders, if that I they helpful I versus this higher something but be going would that don’t expressors are in be

Mani Foroohar

from expense? portion the should And you we think percentage And of clinicians that across more or a types comp guys linear proportionate a think how tissue how to studies you company future and a where growth cardiologist, many stay then pipeline, smaller we broader absolute headcount a R&D question, you’re the types, as as years? trends? say, Like about modeling running different Great. about of to addressing in should expense, of do on larger late-stage that become in on across terms basis different financials oncologist, those stock-based into scale That’s pulmonologist move helpful. as comp expect mid state in you’re

Christopher Anzalone

we question haven’t answer increase any spend. guidance – first sort So we of, given in I’ll haven’t on R&D

given that you bit any We’re quite not us Ken, haven’t prepared address to of give yet a we guidance do this? there. but time, to want

Ken Myszkowski

expense. stock a when non-cash is it’s estimate we really, the of compensation our our equity. issue really to so hard It value because is stock upon based Yes, really

growth I sort give that will sort would use what But on of leave better guidance expense that guide of be. we can’t you really and as So, the of a that out.

Mani Foroohar

Thanks right. All for taking guys. questions the

Christopher Anzalone

you. Thank

Operator

over closing the hand call now you I’ll for Christopher remarks, back proceed. participants. to Anzalone you, may sir, Thank

Christopher Anzalone

Enjoy again for And us of Thank soon. to you talking joining your forward we the all today. look week. you rest to

Operator

you today’s all participating. concludes for Thank that And conference.

disconnect. now may You

Arrowhead Pharmaceuticals (ARWR) 5 May 212021 Q2 Earnings call transcript